Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2/3

NCT01810913

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiat…

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in…

United States613 participantsStarted 2013-03-22

Treatment: Atezolizumab, Biopsy Procedure

All recent trials (6 shown)

Active — Not RecruitingPhase 3

NCT00588770

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell C…

This randomized phase III trial studies chemotherapy to see how well it works with or without bevacizumab in treating patients with head and neck squamous cell…

United States403 participantsStarted 2008-08-08

Treatment: Bevacizumab, Carboplatin

Active — Not RecruitingPhase 1

NCT02567422

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

This phase I trial studies the side effects and best dose of berzosertib (M6620) when given together with cisplatin and radiation therapy in treating patients w…

United States43 participantsStarted 2017-04-17

Treatment: Berzosertib, Cisplatin

Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiat…

All recent trials (6 shown)

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell C…

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiat…

All recent trials (6 shown)

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell C…

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radia…

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage II…

Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck…